Shares of Vectura Group PLC (LON:VEC) have received a consensus recommendation of “Buy” from the eight research firms that are covering the firm. Eight equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is GBX 222.25 ($2.78).

A number of research firms have recently weighed in on VEC. Peel Hunt reaffirmed a “buy” rating and set a GBX 200 ($2.50) price target on shares of Vectura Group PLC in a research note on Thursday, July 28th. Numis Securities Ltd reaffirmed a “buy” rating and issued a GBX 246 ($3.07) price target on shares of Vectura Group PLC in a research report on Thursday, July 28th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a GBX 230 ($2.87) price target on shares of Vectura Group PLC in a research report on Thursday, July 28th. Citigroup Inc. reaffirmed a “buy” rating and issued a GBX 215 ($2.69) price target on shares of Vectura Group PLC in a research report on Thursday, July 28th. Finally, Stifel Nicolaus reissued a “buy” rating and set a GBX 242 ($3.02) price objective on shares of Vectura Group PLC in a report on Friday, July 29th.

Vectura Group PLC (LON:VEC) opened at 149.10 on Monday. The stock’s market cap is GBX 612.23 million. The firm has a 50-day moving average price of GBX 137.65 and a 200-day moving average price of GBX 148.60. Vectura Group PLC has a 12-month low of GBX 122.90 and a 12-month high of GBX 200.10.

In other news, insider Bruno Angelici bought 80,000 shares of the company’s stock in a transaction dated Monday, September 26th. The stock was bought at an average price of GBX 143 ($1.79) per share, for a total transaction of £114,400 ($142,928.54). Also, insider Trevor Phillips sold 240,841 shares of the business’s stock in a transaction on Tuesday, September 27th. The stock was sold at an average price of GBX 139 ($1.74), for a total value of £334,768.99 ($418,252.11).

Vectura Group PLC Company Profile

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.